Xtant Medical Holdings Inc
$ 0.78
-0.26%
26 Dec - close price
- Market Cap 108,643,000 USD
- Current Price $ 0.78
- High / Low $ 0.83 / 0.75
- Stock P/E 77.60
- Book Value 0.36
- EPS 0.01
- Next Earning Report 2026-03-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.04 %
- 52 Week High 0.95
- 52 Week Low 0.34
About
Xtant Medical Holdings, Inc. is a leading entity in the regenerative medicine sector, focused on the development of advanced medical devices and products for orthopedic and neurological surgical applications. Headquartered in Belgrade, Montana, the company is committed to innovating solutions that enhance surgical treatment for complex conditions, ultimately driving improved patient outcomes. By leveraging state-of-the-art technology and a comprehensive research infrastructure, Xtant Medical is well-positioned to capitalize on growth opportunities within the global regenerative medicine market, catering to an expanding client base both domestically and internationally.
Analyst Target Price
$1.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-12 | 2025-05-12 | 2025-03-31 | 2024-11-07 | 2024-08-08 | 2024-04-01 | 2024-02-13 | 2023-11-09 | 2023-08-01 | 2023-05-04 | 2023-03-07 |
| Reported EPS | 0.01 | 0.02 | 0.2791 | -0.0134 | -0.04 | -0.03 | -0.03 | -0.03 | 0.07 | -0.02 | -0.02 | -0.02 |
| Estimated EPS | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | -0.03 | -0.02 |
| Surprise | 0.02 | 0.03 | 0.2891 | 0.0066 | -0.02 | -0.01 | -0.01 | -0.01 | 0.09 | 0 | 0.01 | 0 |
| Surprise Percentage | 200% | 300% | 2891% | 33% | -100% | -50% | -50% | -50% | 450% | 0% | 33.3333% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.005 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XTNT
2025-12-25 15:09:06
Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) experienced a significant surge in short interest by 286.3% in December, reaching 74,418 shares, although this still represents only 0.1% of its shares short. Institutional investors hold a substantial portion of the company's stock, with Vanguard Group Inc. significantly boosting its position and other firms establishing new stakes. Despite beating quarterly EPS estimates, Xtant Medical missed revenue projections, and one analyst firm, BTIG Research, lowered its price target while maintaining a "Buy" rating.
2025-12-23 18:09:06
Xtant Medical (NYSEAMERICAN:XTNT) saw its shares trade above their 200-day moving average, reaching as high as $0.84 on Monday. Despite a "Buy" rating from analysts with an average target of $1.50, the company's recent earnings report showed mixed results, beating EPS estimates but missing revenue expectations. Institutional investors have significantly increased their positions in the medical technology company.
2025-12-17 08:32:00
Three analysts have issued bullish sentiments on healthcare stocks: Xtant Medical Holdings (XTNT), Novan (NOVN), and Adaptive Biotechnologies (ADPT). Craig-Hallum analysts Chase Knickerbocker and William Bonello maintained Buy ratings for XTNT and ADPT, respectively, citing positive outlooks and significant upside potential for Adaptive Biotechnologies.
2025-12-13 20:09:48
Xtant Medical (NYSEAMERICAN:XTNT) recently saw its share price pass above its 200-day moving average, reaching a high of $0.8142 before settling at $0.7250. This comes after BTIG trimmed its price target but maintained a "Buy" rating, while the company reported better-than-expected EPS but missed on revenue. Institutional investors hold a significant portion of the company's stock, and the consensus analyst rating remains "Buy."
2025-12-13 18:09:39
Xtant Medical Holdings Inc. (NYSE American: XTNT) has announced the commercial launch of nanOss Strata, a new synthetic bone graft product. This next-generation graft uses hydroxycarbonapatite (HCA) for enhanced bioactivity and is available in compression-resistant strips and prehydrated moldable forms. The launch follows a strong Q3 2025 earnings report and strategic asset sales, reinforcing Xtant's commitment to innovation in regenerative medicine.
2025-12-13 11:09:29
AWM Investment Company Inc. has acquired a new stake of 6,596,621 shares in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT), valued at approximately $4.88 million, representing 5.06% of the company. Other institutional investors like Jane Street Group LLC, Crescent Grove Advisors LLC, and Nantahala Capital Management LLC have also adjusted their holdings in the medical device company. Xtant Medical reported its quarterly earnings, exceeding analyst estimates for EPS but falling short on revenue, and BTIG Research recently cut its price target to $1.50 with a "buy" rating.
